オプションチェーンは、Repare Therapeuticsの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Repare Therapeuticsの市場センチメントを評価します。.

Repare Therapeutics (NASDAQ:RPTX) 株価情報, オプションチェーン

REPARE THERAPEUTICS INC

Repare Therapeutics

Repare Therapeutics Inc is a precision medicine oncology company focused on the development of synthetic lethality-based therapies for patients with cancer. The Company's focus is the research, development and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient populations.

Repare Therapeutics Inc

Orbit Garant Drilling (TSX:<a class="ticker" href="https://www.benzinga.com/stock/OGD#TSX">OGD</a>) reported quarterly earnings of $0.08 per share. This is a 60 percent increase over earnings of $0.05 per share from the same period last year. The company reported $50.00 million in sales this quarter. This is a 3.73 percent increase over sales of $48.20 million the same period last year.

Earnings

News

TSX:OGD

Orbit Garant Drilling Q3 EPS $0.08 Up From $0.05 YoY, Sales $50.00M Up From $48.20M YoY

Granite Real Estate Inc. Stapled Units, each consisting of one unit of Granite Real Estate Trust and one common share of Granite REIT Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRP#NYSE">GRP</a>) reported quarterly earnings of $1.41 per share which missed the analyst consensus estimate of $1.42 by 0.7 percent. This is a 55.8 percent increase over earnings of $0.91 per share from the same period last year. The company reported quarterly sales of $123.00 million which missed the analyst consensus estimate of $151.10 million by 18.60 percent. This is a 19.35 percent increase over sales of $103.05 million the same period last year.

Earnings Misses

Granite Real Estate Inc. Stapled Units, each consisting of one unit of Granite Real Estate Trust and one common share of Granite REIT Inc.

GRP/U

Granite Real Estate Inc. Stapled Units, each consisting of one unit of Granite Real Estate Trust and one common share of Granite REIT Inc. Q1 FFO $1.41 Misses $1.42 Estimate, Sales $123.00M Miss $151.10M Estimate

kneat.com (TSX:<a class="ticker" href="https://www.benzinga.com/stock/KSI#TSX">KSI</a>) reported quarterly earnings of $0.02 per share which beat the analyst consensus estimate of $(0.02) by 200 percent. This is a 150 percent increase over losses of $(0.04) per share from the same period last year. The company reported quarterly sales of $14.75 million which missed the analyst consensus estimate of $15.62 million by 5.58 percent. This is a 36.97 percent increase over sales of $10.77 million the same period last year.

Earnings Beats

TSX:KSI

kneat.com Q1 EPS $0.02 Beats $(0.02) Estimate, Sales $14.75M Miss $15.62M Estimate

COST

Costco Net Sales For Retail Month Of Apr. Were $21.18B, Up 7% YoY

Merus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRUS#NASDAQ">MRUS</a>) reported quarterly losses of $(1.40) per share which missed the analyst consensus estimate of $(1.10) by 27.27 percent. This is a 137.29 percent decrease over losses of $(0.59) per share from the same period last year. The company reported quarterly sales of $26.49 million which beat the analyst consensus estimate of $7.82 million by 238.85 percent. This is a 235.76 percent increase over sales of $7.89 million the same period last year.

MRUS

Merus Q1 EPS $(1.40) Misses $(1.10) Estimate, Sales $26.49M Beat $7.82M Estimate

McEwen Mining (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MUX#NYSE">MUX</a>) reported quarterly losses of $(0.12) per share which met the analyst consensus estimate. This is a 140 percent decrease over losses of $(0.05) per share from the same period last year. The company reported quarterly sales of $35.70 million which missed the analyst consensus estimate of $41.70 million by 14.40 percent. This is a 13.42 percent decrease over sales of $41.23 million the same period last year.

McEwen Mining Q1 EPS $(0.12), Inline, Sales $35.70M Miss $41.70M Estimate

Compass Minerals Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMP#NYSE">CMP</a>) reported quarterly earnings of $0.63 per share which beat the analyst consensus estimate of $0.01 by 6200 percent. This is a 57.72 percent decrease over earnings of $1.49 per share from the same period last year. The company reported quarterly sales of $494.60 million which beat the analyst consensus estimate of $413.67 million by 19.56 percent. This is a 35.88 percent increase over sales of $364.00 million the same period last year.

Compass Minerals Intl Q2 Adj. EPS $0.63 Beats $0.01 Estimate, Sales $494.60M Beat $413.67M Estimate

Kinaxis (TSX:<a class="ticker" href="https://www.benzinga.com/stock/KXS#TSX">KXS</a>) affirms FY2025 sales outlook from $535.00 million-$550.00 million to $535.00 million-$550.00 million.

Guidance

TSX:KXS

Kinaxis Affirms FY2025 Sales Guidance of $535.00M-$550.00M

SunOpta (TSX:<a class="ticker" href="https://www.benzinga.com/stock/SOY#TSX">SOY</a>) sees FY2025 sales of $788.000 million-$805.000 million vs $790.85 million analyst estimate.

TSX:SOY

SunOpta Sees FY2025 Sales $788.000M-$805.000M vs $790.85M Est

Kinaxis (TSX:<a class="ticker" href="https://www.benzinga.com/stock/KXS#TSX">KXS</a>) reported quarterly earnings of $0.88 per share which beat the analyst consensus estimate of $0.78 by 12.82 percent. This is a 51.72 percent increase over earnings of $0.58 per share from the same period last year. The company reported quarterly sales of $132.79 million which beat the analyst consensus estimate of $132.54 million by 0.19 percent. This is a 11.24 percent increase over sales of $119.37 million the same period last year.

Kinaxis Q1 Adj. EPS $0.88 Beats $0.78 Estimate, Sales $132.79M Beat $132.54M Estimate

Beyond Meat Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BYND#NASDAQ">BYND</a>) reported first-quarter financial results after the market close on Wednesday. Here&#8217;s a rundown <a href="https://www.benzinga.com/pressreleases/25/05/g45266464/beyond-meat-reports-first-quarter-2025-financial-results">of the report</a>.
<ul>
<li>Q1 Revenue: $68.73 million, versus <a href="http://benzinga.com/quote/bynd/earnings">estimates</a> of $75.01 million</li>
</ul>
<ul>
<li>Q1 Adjusted Loss: 67 cents, versus estimates of 48 cents</li>
</ul>
Total revenue was down 9.1% year-over-year. The plant-based meat company noted that its net loss was impacted by legal expenses, strategic decisions to increase provisions for certain inventory items and the suspension of the company&#8217;s operations in China. 
&#8220;As the&nbsp;first quarter&nbsp;of 2025 progressed to a close, we saw a slowdown in consumption as the uncertain macroeconomic environment likely exacerbated category challenges,&#8221; said Ethan Brown, president and CEO of Beyond Meat.
&#8220;Nevertheless, we drove year-over-year reductions in operating expenses, notwithstanding the impact of certain transitory items, to partially offset disappointing net revenues and gross profit.&#8221;
The company ended the quarter with $115.8 million in cash, cash equivalents and restricted cash, as well as $1.1 billion in total outstanding debt. 
In connection with earnings, Beyond Meat announced that it successfully closed a financing facility providing up to&nbsp;$100 million&nbsp;in new senior secured debt from Unprocessed Foods, LLC. 
Outlook: Beyond Meat expects second-quarter net revenue to be in the range of $80 million to $85 million versus estimates of $93.47 million, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Management will further discuss the quarter on a conference call scheduled to begin at 5 p.m. ET.
BYND Price Action: <a href="http://benzinga.com/quote/bynd">Beyond Meat shares</a> were down 5.51% in Wednesday&#8217;s after-hours session, trading at $2.40 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/05/45268589/sunrun-stock-rallies-after-strong-q1-report-details">Sunrun Stock Rallies After Strong Q1 Report: Details</a></li>
</ul>
Photo: courtesy of Beyond Meat.

Movers

BYND

Beyond Meat Reports 'Disappointing' Q1 Results, Issues Soft Guidance Following 'Slowdown' In Consumption, Shares Slide

Chip stocks climbed late Wednesday after Bloomberg <a href="https://www.bloomberg.com/news/articles/2025-05-07/trump-to-rescind-global-chip-curbs-amid-ai-restrictions-debate">reported</a> the Trump administration plans to rescind a key Biden-era export restriction on AI chips. The rollback targets the "AI diffusion rule," which imposed complex licensing rules on sales to dozens of countries.
At market close on Wednesday, NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) shares were up 3.10% to $117.06, Advanced Micro Devices Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>) gained 1.76% to $100.36 and Taiwan Semiconductor Manufacturing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) were higher by 1.31% to $174.54.
What To Know: The diffusion rule, introduced in January, grouped countries into three tiers with varying levels of export restrictions. Nvidia has been a <a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44934100/analyst-sticks-with-nvidia-despite-fallout-from-china-curbs">vocal critic</a>, warning the rules would harm U.S. competitiveness and push allies toward China.
Read Also: <a href="https://www.benzinga.com/trading-ideas/movers/25/05/45259675/apple-alphabet-shares-tumble-amid-potential-ai-search-shift">Apple, Alphabet Shares Tumble Amid Potential AI Search Shift</a>
According to Bloomberg, Trump officials <a href="https://www.bloomberg.com/news/articles/2025-05-07/trump-to-rescind-global-chip-curbs-amid-ai-restrictions-debate">aim to replace</a> the rule with a simpler framework that still targets countries accused of diverting chips to China, including Malaysia and Thailand.
The move comes ahead of Trump&#8217;s planned Middle East trip, where countries like the UAE and Saudi Arabia — previously hit by chip curbs — hope to negotiate better terms.
While the rollback isn't final, the Commerce Department is expected to continue enforcing current restrictions until a new policy is adopted, Bloomberg noted.
Read Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45264199/amd-market-position-is-the-best-in-the-companys-history-says-analyst">AMD Market Position Is &#8216;The Best In The Company&#8217;s History,&#8217; Says Analyst</a>
<h1 class="wp-block-heading">How To Buy AMD Stock</h1>
Besides going to a brokerage platform to purchase a share — or fractional share — of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.
For example, Advanced Micro Devices is in the Information Technology sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
Read Also:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45263291/fed-keeps-rates-steady-warns-of-rising-uncertainty-about-the-economic-outlook">Fed Keeps Rates Steady, Warns Of Rising &#8216;Uncertainty About The Economic Outlook&#8217; </a></li>
</ul>
Photo: Shutterstock

Government

Politics

Global

Tech

NVDA

Chip Stocks Rise As Trump Reportedly Plans To Roll Back Biden-Era AI Export Curbs

Contracts

VECO

Veeco Instruments Received Over $35M In Orders For Its AP300 Lithography Systems In Recent Quarters

Savaria (TSX:<a class="ticker" href="https://www.benzinga.com/stock/SIS#TSX">SIS</a>) reported quarterly earnings of $0.23 per share which met the analyst consensus estimate. This is a 15 percent increase over earnings of $0.20 per share from the same period last year. The company reported quarterly sales of $220.23 million which missed the analyst consensus estimate of $221.80 million by 0.71 percent. This is a 5.15 percent increase over sales of $209.44 million the same period last year.

TSX:SIS

Savaria Q1 Adj. EPS $0.23, Inline, Sales $220.23M Miss $221.80M Estimate

SunOpta (TSX:<a class="ticker" href="https://www.benzinga.com/stock/SOY#TSX">SOY</a>) reported quarterly earnings of $0.04 per share which missed the analyst consensus estimate of $0.05 by 20 percent. This is a 100 percent increase over earnings of $0.02 per share from the same period last year. The company reported quarterly sales of $201.63 million which beat the analyst consensus estimate of $199.02 million by 1.31 percent. This is a 10.27 percent increase over sales of $182.85 million the same period last year.

SunOpta Q1 Adj. EPS $0.04 Misses $0.05 Estimate, Sales $201.63M Beat $199.02M Estimate

Manulife Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MFC#NYSE">MFC</a>) reported quarterly earnings of $0.69 per share. This is a 1.43 percent decrease over earnings of $0.70 per share from the same period last year. The company reported $1.49 billion in sales this quarter. This is a 7.27 percent increase over sales of $1.39 billion the same period last year.

Manulife Financial Q1 Adj. EPS $0.69 Down From $0.70 YoY, Sales $1.49B Up From $1.39B YoY

WLGS

WANG & LEE GROUP Receives Letter From Nasdaq Regarding Continued Listing Requirement

A growing chorus of economists is sounding the alarm that stagflation — a toxic mix of sluggish growth, rising unemployment, and persistent inflation — is no longer a distant threat but the most probable path <a href="https://www.benzinga.com/topic/federal-reserve">for the U.S. economy.</a>
Reacting to the May Federal Open Market Committee meeting and Chair Jerome Powell's remarks, economists viewed the Fed's acknowledgment that "risks of higher unemployment and higher inflation have risen" as a clear admission that the economy <a href="https://www.benzinga.com/government/regulations/25/05/45266366/powell-flags-sharp-tariff-shock-elevated-uncertainty-fed-sticks-to-wait-and-see-mode">has entered a stagflationary phase. </a>
This unwelcome scenario that hasn&#8217;t dominated forecasts since the 1970s now sharply complicates the central bank's policy path moving forward.
"The Federal Reserve left interest rates unchanged and signaled the higher probability of a stagflationary wind," said Mohamed El-Erian, chief economic adviser at Allianz.
Justin Wolfers, a professor at the University of Michigan, summed up the concern in starker terms: "Never a good moment when your central bank says that it&#8217;s worried about both higher unemployment and higher inflation. That&#8217;s a problem that monetary policy alone can&#8217;t solve."
<h3 class="wp-block-heading">Markets Rethink Rate Cut Timeline</h3>
Financial markets swiftly adjusted expectations for monetary easing. The probability of a 25-basis-point rate cut in June fell to 23%, down from 28% prior to Powell's remarks, according to CME FedWatch data. 
July still carries a 72% chance for a cut, but the window for rate reliefs appears to be narrowing.
Oxford Economics chief U.S. economist Ryan Sweet said the Fed's response to the current situation will be reactive, not preemptive. 
"The Fed is unlikely to cut interest rates earlier than our forecast of December, unless there are definitive signs that the labor market is deteriorating," he said.
The initial impact of tariffs might be disinflationary, Sweet added. That&#8217;s due to weaker travel prices and falling energy costs. But higher prices will likely emerge later this year, especially as global supply chains absorb new trade restrictions, he warns.
During his press conference, Powell offered a blunt reminder: this is not 2019. 
Back then, the Fed delivered three rate cuts in response to a slowing economy and tame inflation at 1.6%. But with core inflation now running above 2% for four straight years, the Fed's flexibility is constrained.
Charlie Ripley, senior investment strategist at Allianz Investment Management, said the Fed is staying data-driven while others push for immediate action. 
"Despite volatile markets, the current state of the U.S. economy shows expanded activity at a solid pace," he said. "Patience is a virtue, and the Fed seemingly has an abundance of it relative to other market participants."
Macro analyst Otavio Costa from Crescat Capital reminded that a year ago, Powell said that he doesn&#8217;t see &#8220;the stag, nor the flation.&#8221;
"Today, the Fed's projections anticipate both. This is a timely reminder that we're still grappling with a rare trifecta: inflation like the 1970s, debt like the 1940s, and equity valuations like the late 1920s," he said in a post on social media X. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Almost exactly one year ago, Jay Powell said: &quot;I don&#39;t see the stag, nor the &#39;flation.&#39;&quot; Today, the Fed's projections anticipate both. This is a timely reminder that we're still grappling with a rare trifecta of macro imbalances: Inflation like the 1970s, government debt… <a href="https://t.co/OKiiXDkyQp">pic.twitter.com/OKiiXDkyQp</a>
&mdash; Otavio (Tavi) Costa (@TaviCosta) <a href="https://twitter.com/TaviCosta/status/1920191640393986369?ref_src=twsrc%5Etfw">May 7, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
<h3 class="wp-block-heading">Could The Fed Be Too Late?</h3>
Chris Zaccarelli, chief investment officer at Northlight Asset Management, sees the Federal Reserve caught between the opposing forces of rising inflation and a weakening economy. 
He said the Fed may be forced to delay rate cuts until unemployment climbs sharply, which could risk acting too late. 
&#8220;The markets are going to increasingly worry about a recession and unless some trade deals are made before the tariff pause runs out, we are going to see markets drop again like they did in early April,&#8221; he said. 
Read now: 
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45263291/fed-keeps-rates-steady-warns-of-rising-uncertainty-about-the-economic-outlook">Fed Keeps Rates Steady, Warns Of Rising &#8216;Uncertainty About The Economic Outlook&#8217;</a></li>
</ul>
Image: Shutterstock

Analyst Color

Macro Economic Events

Econ #s

Economics

Analyst Ratings

Stagflation Emerges As Key Risk To Fed Policy, Economists Warn: 'We're Grappling With A Rare Trifecta'

Biotech

General

Telix Pharmaceuticals Publishes Fibroblast Activation Protein-Targeting Therapy Candidate In Thyroid Journal

Watts Water Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WTS#NYSE">WTS</a>) raises FY2025 sales outlook from $2.19 billion-$2.30 billion to $2.21 billion-$2.32 billion vs $2.26 billion estimate.

Watts Water Technologies Raises FY2025 Sales Guidance from $2.19B-$2.30B to $2.21B-$2.32B vs $2.26B Est

Press Releases

Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial

Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial

Opinion

How Cutting-Edge Immunotherapies Are Redefining Cancer Treatment Options

Repare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost Reductions

Repare Therapeutics Provides Business and Clinical Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Repare Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Repare Therapeutics Announces Leadership Transitions

Repare Therapeutics Announces Six Abstracts Accepted for Presentation at AACR Annual Meeting 2025

Repare Therapeutics Announces Out-Licensing of its Discovery Platforms to DCx Biotherapeutics

Newly Launched DCx Biotherapeutics In-Licenses Discovery Platforms and Retains Talent and Infrastructure From Repare Therapeutics to Accelerate Development of Multi-Modal Antibody Drug Conjugates

Comments

Repare Therapeutics

Repare Therapeutics (RPTX) オプション

Repare Therapeutics (NASDAQ:RPTX) 株価情報, オプションチェーン

ニュース

パートナーシップ

ベンジンガ・グローバル